Skip to main content
Fig. 4 | BMC Complementary Medicine and Therapies

Fig. 4

From: PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma

Fig. 4

PAMs reduced tumor growth, similar to MAO A inhibitor clorgyline in subcutaneous mouse glioma C57BL/6 mouse model. Mice were implanted subcutaneously with 5 × 103 luciferase-positive mouse glioma GL-26 cells, then were treated with MAO A inhibitor clorgyline (10 mg/kg), PAMs (48 mg/kg), and vehicle for 14 days. a Tumor sizes were reduced by PAMs and clorgyline at day 8 after the implantation of GL-26 cells in C57BL/6 mice as shown by images. Representative images of tumor size reduced by PAMs or clorgyline on day 0 and 8 after treatment were shown. b Qualitative representation of bioluminescence imaging conducted at day 8. c PAMs and clorgyline reduced tumor size at day 13 in subcutaneously implanted GL-26 cells in C57BL/6 mice. d PAMs and clorgyline reduced tumor size compared to vehicle. e MAO A catalytic activity was reduced by PAMs and clorgyline. f No change in body weight was observed for all three groups, i.e. PAMs, clorgyline, and vehicle. Each group n = 5. Data represent the mean ± SEM. The p-value was calculated by t-test. *p < 0.05, PAMs group compared to vehicle, #p < 0.05 clorgyline compared to vehicle

Back to article page
\